A collection of representative B2B lead discovery scenarios, showing how AI identifies qualified sales opportunities from real-world business conversations.
How to Verify a Clinical Trial Site When the Deadline Is Already Shrinking
A multicenter study still lacks qualified sites while ethics and activation schedules are tightening. This illustrative scenario walks through what a clinical operations lead can verify before the deadline locks in a bad
This is an illustrative scenario designed to explain the product’s judgement logic. It is not a real customer case, testimonial, contract, revenue result, or conversion claim.
01Situation
02Signal judgement
03Confidence vs priority
04Human next step
Signals considered
- deadline-driven site selection
- site verification sequence
- feasibility vs activation
Illustrative scenario. This article explains business-signal judgement and human verification. It does not represent a real customer, conversation, contract, revenue result or conversion claim.
A Multicenter Study That Still Needs Sites
You are six weeks from the first planned activation, and your site list is still short by four qualified centers. The indication is oncology — a specific biomarker-defined subtype — and the countries involved require independent ethics review per site. Every week the CRO sends an updated tracker showing sites under “feasibility review,” but the column that matters most, “contracting & budget approved,” stays empty. Meanwhile, the principal investigator at one candidate site keeps asking for the full protocol despite the site having no previous experience in this biomarker subtype.
This is an illustrative business scenario. No real customer, data point, or result is claimed.
The dilemma is familiar to any clinical operations lead who has managed a tight activation timeline: the pressure to say yes to any site that responds quickly. But a fast yes from a site that cannot recruit compatible patients, or that lacks the ethics infrastructure to clear the first submission, will cost more time than it saves.
Why Keywords and Urgency Are Not Enough
When a site says it is “interested” and “experienced in oncology,” the words alone carry little diagnostic weight. Interest is cheap until the budget negotiation begins. Oncology experience at one institution may mean early-stage solid tumors only, while your protocol requires relapsed/refractory patients with a rare biomarker. The same gap applies to geography: a site in the right city may serve a catchment population that does not match the enrollment target’s demographic profile.
The signals that are easy to collect — email responsiveness, enthusiasm, a signed confidentiality agreement — are almost the same for a genuinely capable site and one that will fail feasibility. The difference is invisible without structured verification. Relying on keyword matching in site databases or CRO tracker fields labeled “status” simply repeats the ambiguity the tracker was meant to resolve. What looks like progress is often a placeholder.
Seven variables require independent confirmation before you can treat a candidate as viable: indication and biomarker subtype alignment, geographic catchment, site capability and prior trial complexity, enrollment target feasibility, ethics submission ownership and timeline, contracting authority and standard cycle time, and the actual deadline — is it driven by a regulatory filing, a grant milestone, or internal planning? Each of these can be verified with a phone call or a document request. None of them can be inferred from a tracker status field.
Evidence to Verify Before You Commit
The verification sequence should follow a fixed order so that a failure at any step stops work before time is wasted on the next.
Start with indication and biomarker fit. Ask the site coordinator or principal investigator for the number of patients with the exact biomarker definition your protocol uses who were seen at that site in the last twelve months. A ballpark estimate is not sufficient — ask for a count from the pathology or oncology database. If the site cannot produce it, the site cannot forecast enrollment.
Next, confirm ethics submission ownership. Some sites delegate ethics to a central institutional review board; others require local committee approval. The difference in timeline can be six to twelve weeks. Ask who prepares the submission, what their backlog looks like, and when the next committee meeting is scheduled. Write down the date.
Then verify contracting authority and cycle time. Is the contracting handled by a dedicated office, and what is their standard turnaround for a multicenter study at your stage? A site that says “we move fast on contracts” but cannot name the office or the standard cycle should be deprioritized until the information is provided.
Cross-check enrollment target feasibility against the site’s confirmed patient count. A site that expects to enroll eight patients but has seen three eligible patients in the past year is not conservative — it is optimistic in a way that will create a shortfall. The enrollment forecast should be no more than half the confirmed count.
The Human Next Step
Once you have collected these seven data points, the next step is to separate the sequence into three distinct phases: site introduction, feasibility review, and formal selection. These should not be collapsed into a single conversation.
During the site introduction, confirm indication fit and ethics ownership only. Do not open budget discussions or ask for a commitment. The goal is to determine whether the site passes two gates: does it have the right patients, and can it clear ethics within your timeline? If either answer is no, close the candidate before spending any further internal time.
If both pass, move to the feasibility review. Send a structured feasibility questionnaire that asks for the same seven variables in writing, signed by the site’s research office. Compare the written answers to your phone call notes. Discrepancies here are a hard stop — they indicate either a misunderstanding of the protocol or a site that is delegating the response to someone without authority. Either reason is sufficient to pause.
Only after the written feasibility questionnaire is returned and consistent should you begin formal selection: budget negotiation, contracting, and the activation timeline. At this stage, the study’s legal and compliance teams should own the process. The clinical operations lead’s role is to verify that the site has passed all prior gates, not to chase signatures.
What Community Messages Cannot Prove
A site coordinator’s email that says “we can handle this indication” or “ethics usually takes four weeks here” is not evidence. Neither is a CRO status field labeled “feasibility in progress.” The information that matters — confirmed patient counts, ethics committee dates, contracting cycle times — exists only in documents and in conversations with the people who hold those documents. Shortcutting the verification sequence because the deadline is tight is the most common reason a site drops out after activation, leaving a gap that takes twice as long to fill.
Deadlines concentrate the mind. They should not collapse the process. Preserve human responsibility for verifying identity, authority, budget, compliance, and the final decision to activate or walk away.
Frequently asked questions
Does this scenario describe a real customer?
No. This is an illustrative scenario built from common industry patterns. No customer, quotation, revenue figure, or conversion metric is real or claimed.
What is the most dangerous shortcut in deadline site recruitment?
Skipping independent verification of indication fit and ethics ownership. A site that looks fast on paper can stall the entire study if those two are wrong.